Attention Investors: Don’t Miss Out on the Upcoming Deadline! Join the Class Action Lawsuit Against WEBTOON Entertainment Inc. with Robbins Geller Rudman & Dowd LLP

Welcome to the World of WEBTOON Entertainment Inc. What’s the Buzz About? San Diego, Oct. 29, 2024 – Exciting news in the world of entertainment as WEBTOON Entertainment Inc. (NASDAQ: WBTN) makes waves with their recent initial public offering (IPO). Investors and fans alike have been keeping a close eye on WEBTOON, and now there’s…

Read More

Rambus Inc. (RMBS) Q3 2024 Earnings Call Transcript

Rambus Inc. Q3 2024 Earnings Conference Call Company Participants: Desmond Lynch – Chief Financial Officer Luc Seraphin – President and Chief Executive Officer Conference Call Participants: Kevin Cassidy – Rosenblatt Securities Blayne Curtis – Jefferies Mehdi Hosseini – SIG Nam Kim – Arete Research Gary Mobley – Loop Capital Welcome to the Rambus Third Quarter…

Read More

First Patient Enrolled in BioPorto’s US Study of ProNephro AKI NGAL for Adult Use at Massachusetts General Hospital

October 29, 2024 Announcement no. 20 First Patient In – BioPorto Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL)™ for Adult Use at Massachusetts General Hospital COPENHAGEN, Denmark and BOSTON, MA, USA, October 29, 2024, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the…

Read More

Is Bitcoin on the Verge of Surpassing $70,000? A Closer Look at the Future of the Leading Cryptocurrency

Bitcoin Hits $70,000 as US Presidential Election Nears The Current State of Bitcoin As the US presidential election draws near, Bitcoin has briefly surged to the $70,000 mark for the first time in over five months. This significant milestone has caught the attention of investors and cryptocurrency enthusiasts alike, sparking discussions on how the election…

Read More

Novartis Continues Strong Momentum in Q3 with 10% Sales Growth, 20% Core Operating Income Growth, and Important Innovation Milestones – Raises FY 2024 Guidance

Novartis Q3 2024 Financial Results Q3 net sales grew by 10% Novartis has announced its Q3 2024 financial results, showing a significant growth in net sales of 10%. This growth was mainly driven by the continued strong performance of key products such as Entresto, Cosentyx, Kisqali, Kesimpta, Pluvicto, and Leqvio. Core operating income up by…

Read More